Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pembrolizumab + capecitabine/oxaliplatin (CapeOx) in metastatic gastric cancer as first-line treatment
KCT0004775Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, capecitabine, oxaliplatin in gastric cancer (GC), sponsored by Samsung Medical Center. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0004775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004775.